Leaderboards/her2 egfr in cancer research

her2 egfr in cancer research

Last updated June 2, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Jinzhuo Wang
Center for Life Sciences
99
2
Jia Qu
Wenzhou Medical University
90
3
Kanwal Raghav
The University of Texas MD Anderson Cancer Center
70
4
Chao Wang
Shandong University
60
5
Lin Han
Shandong University
50
6
Carolina Sousa
University of Lisbon
40
7
Mafalda Videira
University of Lisbon
30
8
Vũ Minh Trang
Hanoi National University of Education
20
9
Phan Minh Giang
Vietnam National University, Hanoi
10

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
David Johnson
Prince of Wales Hospital
99
2
Abdulaziz A. Alotaibi
King Saud University
90
3
Kabir M. Uddin
North South University
80
4
Sadaf Mutahir
Linyi University
60
5
Ye Jin Lim
Konkuk University
50
6
Kritant Bhushan
Unknown
40
7
Megha Jethwa
University of Calcutta
30
8
Huilan Zeng
Chongqing University
20
9
Walla I. Malkawi
University of Iowa
10

Emerging Leaders Papers

1
Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells
Molecules|2024
8 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Solange Peters
University Hospital of Lausanne
99
2
Alok C. Bharti
The University of Texas MD Anderson Cancer Center
90
3
Balázs Győrffy
Semmelweis University
80
4
Joachim von Pawel
Unknown
70
5
José Baselga
Harvard University
60
6
Geoffrey R. Oxnard
Dana-Farber Cancer Institute
50
7
Tony Mok
Chinese University of Hong Kong
40
8
Eric P. Winer
Dana-Farber Cancer Institute
30
9
Laurence Lousberg
Centre Hospitalier Universitaire de Liège
20
10
Lijun Cheng
Indiana University – Purdue University Indianapolis
10

All-Time Leaders Papers

1
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Annals of Oncology|2018
2.9k cit.
2
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Annals of Oncology|2016
2.1k cit.
3
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
PLoS ONE|2013
1.9k cit.
4
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
JNCI Journal of the National Cancer Institute|2007
876 cit.
5
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Journal of Clinical Oncology|2020
541 cit.
6
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Journal of Clinical Oncology|2005
409 cit.
7
Targeted therapies for breast cancer
Journal of Clinical Investigation|2011
371 cit.
8
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
The Breast|2014
332 cit.
9
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
Clinical Cancer Research|2004
277 cit.
10
Evidence That Receptor Activator of Nuclear Factor (NF)-κB Ligand Can Suppress Cell Proliferation and Induce Apoptosis through Activation of a NF-κB-independent and TRAF6-dependent Mechanism
Journal of Biological Chemistry|2004
103 cit.

Indexing her2 egfr in cancer research Reagents

Citation data for reagents in this field is currently compiling.